Michelle Glasgow

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer

Elena Ratner, Florence K. Keane, Robert Lindner et al. · Oncogene · 2011 · 82 citations · Full text

Medicine, Kras Variant, Pathology +11

Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service

Elizabeth L. Dickson, Erica Stockwell, Melissa A. Geller et al. · Obstetrics and Gynecology · 2017 · 62 citations

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)

Michelle Glasgow, Herbert Yu, Thomas Rutherford et al. · Journal of Surgical Oncology · 2012 · 60 citations

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

Dana M. Roque, Natália Buza, Michelle Glasgow et al. · Clinical & Experimental Metastasis · 2013 · 51 citations · Full text

Poor Overall Survival, Medicine, Metronomic Therapy +9

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor

Emiliano Cocco, Joyce Varughese, Natália Buza et al. · BMC Cancer · 2011 · 44 citations · Full text